Compare Stocks: ELAN, ONC, RPRX, and ZTS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELAN Elanco Animal Health	$22.92 +2.2%	$24.24	$18.48 ▼ $27.98	$11.21B	1.68	4.90 million shs	5.61 million shs
ONC BeOne Medicines	$368.08 +0.7%	$346.79	$253.95 ▼ $385.22	$40.15B	0.51	343,362 shs	262,916 shs
RPRX Royalty Pharma	$58.52 +0.1%	$59.55	$34.63 ▼ $64.38	$33.60B	0.44	3.10 million shs	2.69 million shs
ZTS Zoetis	$72.76 +2.0%	$75.20	$70.26 ▼ $148.79	$29.48B	0.73	4.54 million shs	3.84 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELAN Elanco Animal Health	+1.91%	-0.45%	-4.70%	-4.33%	+20.11%
ONC BeOne Medicines	+0.66%	+6.23%	-1.71%	+32.82%	+8.96%
RPRX Royalty Pharma	+0.14%	+0.09%	-4.55%	+7.90%	+63.19%
ZTS Zoetis	+2.00%	-0.90%	-6.38%	-6.88%	-49.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELAN Elanco Animal Health	$22.92 +2.2%	$24.24	$18.48 ▼ $27.98	$11.21B	1.68	4.90 million shs	5.61 million shs
ONC BeOne Medicines	$368.08 +0.7%	$346.79	$253.95 ▼ $385.22	$40.15B	0.51	343,362 shs	262,916 shs
RPRX Royalty Pharma	$58.52 +0.1%	$59.55	$34.63 ▼ $64.38	$33.60B	0.44	3.10 million shs	2.69 million shs
ZTS Zoetis	$72.76 +2.0%	$75.20	$70.26 ▼ $148.79	$29.48B	0.73	4.54 million shs	3.84 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELAN Elanco Animal Health	+1.91%	-0.45%	-4.70%	-4.33%	+20.11%
ONC BeOne Medicines	+0.66%	+6.23%	-1.71%	+32.82%	+8.96%
RPRX Royalty Pharma	+0.14%	+0.09%	-4.55%	+7.90%	+63.19%
ZTS Zoetis	+2.00%	-0.90%	-6.38%	-6.88%	-49.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELAN Elanco Animal Health	2.77	Moderate Buy	$29.09	26.92% Upside
ONC BeOne Medicines	3.00	Buy	$402.71	9.41% Upside
RPRX Royalty Pharma	3.00	Buy	$61.29	4.73% Upside
ZTS Zoetis	2.32	Hold	$101.08	38.92% Upside

Current Analyst Ratings Breakdown

Latest ELAN, ONC, RPRX, and ZTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/10/2026	ONC BeOne Medicines	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$407.00 ➝ $415.00
9/9/2026	ZTS Zoetis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/8/2026	RPRX Royalty Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$65.00 ➝ $68.00
9/4/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/25/2026	ZTS Zoetis	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$104.00 ➝ $94.00
8/25/2026	ZTS Zoetis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$94.00
8/20/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/20/2026	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$85.00 ➝ $80.00
8/12/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
8/11/2026	ZTS Zoetis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$112.00 ➝ $96.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELAN Elanco Animal Health	$4.72B	2.43	$2.37 per share	9.67	$13.18 per share	1.74
ONC BeOne Medicines	$5.34B	7.56	$3.93 per share	93.56	$39.77 per share	9.26
RPRX Royalty Pharma	$2.38B	14.15	$4.78 per share	12.23	$16.83 per share	3.48
ZTS Zoetis	$9.47B	3.18	$7.72 per share	9.43	$7.56 per share	9.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	17.77	1.60	-3.96%	8.13%	3.99%	11/6/2026 (Estimated)
ONC BeOne Medicines	$286.93M	$5.68	64.80	27.01	N/A	10.70%	14.23%	7.82%	N/A
RPRX Royalty Pharma	$770.95M	$1.45	40.36	10.58	1.38	32.14%	30.01%	14.91%	11/4/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.07	11.99	11.49	1.66	27.49%	74.89%	18.59%	11/3/2026 (Estimated)

Latest ELAN, ONC, RPRX, and ZTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ZTS Zoetis	$1.85	$1.87	+$0.02	$1.65	$2.50 billion	$2.47 billion
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion
8/5/2026	Q2 2026	RPRX Royalty Pharma	$1.27	$1.32	+$0.05	$0.04	$758.93 million	$674.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.61%	+24.01%	64.83%	5 Years
ZTS Zoetis	$2.12	2.91%	+20.11%	34.93%	14 Years

Latest ELAN, ONC, RPRX, and ZTS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.6%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELAN Elanco Animal Health	0.58	2.05	1.10
ONC BeOne Medicines	0.17	3.40	3.06
RPRX Royalty Pharma	0.88	2.80	2.80
ZTS Zoetis	2.87	3.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELAN Elanco Animal Health	97.48%
ONC BeOne Medicines	48.55%
RPRX Royalty Pharma	54.35%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
ELAN Elanco Animal Health	1.14%
ONC BeOne Medicines	6.19%
RPRX Royalty Pharma	18.84%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable
ONC BeOne Medicines	12,000	109.79 million	102.99 million	N/A
RPRX Royalty Pharma	100	575.00 million	466.67 million	Optionable
ZTS Zoetis	14,500	413.22 million	412.32 million	Optionable

ELAN, ONC, RPRX, and ZTS Headlines

Recent News About These Companies

Zoetis (NYSE:ZTS) Reaches New 52-Week Low - Should You Sell?

September 21 at 11:19 AM | marketbeat.com

Nykredit A S Buys New Position in Zoetis Inc. $ZTS

September 21 at 3:36 AM | marketbeat.com

Zoetis stock lags market as analysts brace for earnings decline

September 19, 2026 | ad-hoc-news.deA

Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note

September 18, 2026 | zacks.com

10 large and mega-cap US healthcare stocks with the weakest momentum grades

September 18, 2026 | msn.com

Zoetis (ZTS) Stock Fair Value Falls After Mixed Analyst Cuts And Softer Growth Views

September 18, 2026 | finance.yahoo.com

Zoetis: The Worst May Be Priced In

September 18, 2026 | seekingalpha.com

Zoetis: The Worst May Be Priced In

September 18, 2026 | seekingalpha.com

Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales

September 18, 2026 | marketbeat.com

Zoetis: Companion Animal Weakness Keeps Me On The Sidelines

September 17, 2026 | seekingalpha.com

Zoetis: An Undervalued Compounder Hiding In Plain Sight

September 17, 2026 | seekingalpha.com

Zoetis: New Competition Changes The Story, But Not Yet The Rating

September 17, 2026 | seekingalpha.com

Allworth Financial LP Cuts Holdings in Zoetis Inc. $ZTS

September 15, 2026 | marketbeat.com

Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Corient Private Wealth LP Has $35.07 Million Holdings in Zoetis Inc. $ZTS

September 14, 2026 | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Baird Financial Group Inc.

September 14, 2026 | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Capital Analysts LLC

September 14, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Has $16.64 Million Position in Zoetis Inc. $ZTS

September 13, 2026 | marketbeat.com

National Pension Service Raises Stock Holdings in Zoetis Inc. $ZTS

September 12, 2026 | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Cidel Asset Management Inc.

September 12, 2026 | marketbeat.com

Engineers Gate Manager LP Increases Stock Position in Zoetis Inc. $ZTS

September 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ELAN, ONC, RPRX, and ZTS Company Descriptions

Elanco Animal Health NYSE:ELAN

$22.92 +0.49 (+2.18%)

Closing price 09/22/2026 03:59 PM Eastern

Extended Trading

$22.94 +0.01 (+0.07%)

As of 09/22/2026 07:34 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

BeOne Medicines NASDAQ:ONC

$368.08 +2.41 (+0.66%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$367.78 -0.30 (-0.08%)

As of 09/22/2026 07:30 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Royalty Pharma NASDAQ:RPRX

$58.52 +0.08 (+0.14%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$58.36 -0.16 (-0.28%)

As of 09/22/2026 07:56 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zoetis NYSE:ZTS

$72.76 +1.43 (+2.00%)

Closing price 09/22/2026 03:59 PM Eastern

Extended Trading

$72.82 +0.07 (+0.09%)

As of 09/22/2026 07:56 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELAN, ONC, RPRX, and ZTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELAN, ONC, RPRX, and ZTS Earnings

Compare Dividends

Latest ELAN, ONC, RPRX, and ZTS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELAN, ONC, RPRX, and ZTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ELAN, ONC, RPRX, and ZTS Company Descriptions

Elanco Animal Health NYSE:ELAN

BeOne Medicines NASDAQ:ONC

Royalty Pharma NASDAQ:RPRX

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools